Meyka Pro banner
Scienture Holdings, Inc.

Scienture Holdings, Inc. Fundamental Analysis (NASDAQ: SCNX)

SCNX●NASDAQ
HealthcareMedical - Pharmaceuticals
$0.26
$0.008(3.08%)
U.S. Market opens in 17h 27m

Scienture Holdings, Inc. Fundamental Analysis (NASDAQ: SCNX)

Scienture Holdings, Inc. (NASDAQ: SCNX) shows weak financial fundamentals with a PE ratio of -0.14, profit margin of -46.21%, and ROE of -53.51%. The company generates $0.0B in annual revenue with weak year-over-year growth of 2.16%.

Key Strengths

Cash Position79.56%
PEG Ratio-0.01
Current Ratio3.04

Areas of Concern

ROE-53.51%
Operating Margin-16.71%
We analyze SCNX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -3471.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-3471.4/100

We analyze SCNX's fundamental strength across five key dimensions:

Efficiency Score

Weak

SCNX struggles to generate sufficient returns from assets.

ROA > 10%
-43.26%

Valuation Score

Excellent

SCNX trades at attractive valuation levels.

PE < 25
-0.14
PEG Ratio < 2
-0.01

Growth Score

Weak

SCNX faces weak or negative growth trends.

Revenue Growth > 5%
2.16%
EPS Growth > 10%
-2.00%

Financial Health Score

Excellent

SCNX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.17
Current Ratio > 1
3.04

Profitability Score

Weak

SCNX struggles to sustain strong margins.

ROE > 15%
-5350.82%
Net Margin ≥ 15%
-46.21%
Positive Free Cash Flow
No

Key Financial Metrics

Is SCNX Expensive or Cheap?

P/E Ratio

SCNX trades at -0.14 times earnings. This suggests potential undervaluation.

-0.14

PEG Ratio

When adjusting for growth, SCNX's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values Scienture Holdings, Inc. at 0.16 times its book value. This may indicate undervaluation.

0.16

EV/EBITDA

Enterprise value stands at -0.23 times EBITDA. This is generally considered low.

-0.23

How Well Does SCNX Make Money?

Net Profit Margin

For every $100 in sales, Scienture Holdings, Inc. keeps $-46.21 as profit after all expenses.

-46.21%

Operating Margin

Core operations generate -16.71 in profit for every $100 in revenue, before interest and taxes.

-16.71%

ROE

Management delivers $-53.51 in profit for every $100 of shareholder equity.

-53.51%

ROA

Scienture Holdings, Inc. generates $-43.26 in profit for every $100 in assets, demonstrating efficient asset deployment.

-43.26%

Following the Money - Real Cash Generation

Operating Cash Flow

Scienture Holdings, Inc. generates limited operating cash flow of $-14.81M, signaling weaker underlying cash strength.

$-14.81M

Free Cash Flow

Scienture Holdings, Inc. generates weak or negative free cash flow of $-14.81M, restricting financial flexibility.

$-14.81M

FCF Per Share

Each share generates $-0.36 in free cash annually.

$-0.36

FCF Yield

SCNX converts -1.36% of its market value into free cash.

-1.36%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.14

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.16

vs 25 benchmark

P/S Ratio

Price to sales ratio

13.10

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.17

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.54

vs 25 benchmark

ROA

Return on assets percentage

-0.43

vs 25 benchmark

ROCE

Return on capital employed

-0.16

vs 25 benchmark

How SCNX Stacks Against Its Sector Peers

MetricSCNX ValueSector AveragePerformance
P/E Ratio-0.1430.63 Better (Cheaper)
ROE-53.51%570.00% Weak
Net Margin-4620.92%24326.00% Weak
Debt/Equity0.170.52 Strong (Low Leverage)
Current Ratio3.045.69 Strong Liquidity
ROA-43.26%-59.00% (disorted) Weak

SCNX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Scienture Holdings, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-99.99%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

94.52%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

-1922.50%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ